To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
91 Current news about the topic phase ii studies
rss
Circassia’s cat allergy treatment shows sustained symptom improvement
26-02-2013
Imperial Innovations Group plc announced that portfolio company Circassia has seen strong results from its follow up phase II clinical trial. Patients saw a sustained improvement of their cat allergy symptoms two years after they started a four-dose, 12 week course of Circassia’s ToleroMune® ...
Mesoblast’s Neofuse stem cell product shows positive results in Phase 2 lumbar fusion trial
Results support progression of clinical development to Phase 3
16-01-2013
Mesoblast Limited announced that its Phase 2 clinical trial for lumbar spinal fusion had met its safety and efficacy endpoints. The results suggest that Mesoblast’s NeoFuse product comprising allogeneic Mesenchymal Precursor Cells (MPCs) is as effective for interbody lumbar fusion as the gold ...
CAVATAK Phase II Melanoma Study achieves interim efficacy subgoal
20-12-2012
Viralytics Limited (VLA) in its US-based Phase II melanoma trial of its virotherapy candidate CAVATAKTM has achieved an interim efficacy subgoal of three Objective Responses (OR). This follows a recent review by the independent Data Monitoring Committee (DMC) of the trial. In the Phase II ...
AOP Orphan Pharmaceuticals: Positive Phase II Data of Novel Mono-Pegylated Interferon Alpha 2b for Treatment of Polycythemia Vera
17-12-2012
AOP Orphan Pharmaceuticals AG (AOP Orphan) announced that based on phase II data it will initiate a phase III trial to support European Marketing Authorization of a novel mono-pegylated Interferon alpha 2b (AOP2014/P1101) for treatment of Polycythemia Vera (PV). Data from 41 PV patients ...
Elacytarabine in combination with idarubicin shows promising efficacy in Phase II trial in acute myeloid leukaemia
14-12-2012
Clavis Pharma ASA announces data from its Phase II clinical trial with elacytarabine in combination with idarubicin. The trial enrolled patients with early stage acute myeloid leukaemia (AML), for whom cytarabine-containing first-course chemotherapy has failed. The results found that ...
Keryx Biopharmaceuticals Initiates Phase 2 Study of Zerenex for the Treatment of Non-Dialysis Dependent Chronic Kidney Disease
07-11-2012
Keryx Biopharmaceuticals, Inc. announced the initiation of a Phase 2 study of Zerenex™ (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate, in managing serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney ...
Medivir announces a phase II all-oral study of Simeprevir (TMC435) and VX-135 for the treatment of Hepatitis C to be conducted by Janssen and Vertex
07-11-2012
Medivir AB announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s protease inhibitor simeprevir and Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Janssen will conduct a ...
Poxel's Anti-diabetic Imeglimin Shows Significant Clinical Benefits in Type 2 Diabetes when Added to Sitagliptin
Phase II study achieved primary and secondary endpoints
07-11-2012
Poxel SA announced that in a Phase II study Imeglimin, a novel compound in development for Type 2 diabetes, showed incremental efficacy as an add-on therapy to sitagliptin, in patients inadequately controlled by sitagliptin monotherapy. The study achieved its primary endpoint of superiority ...
VAXIMM completes enrollment of first oral cancer vaccine trial
25-10-2012
VAXIMM AG announced that it completed enrollment in the first clinical trial of its investigational oral therapeutic cancer vaccine VXM01. The randomized, placebo-controlled, double-blind Phase I/II dose escalation study enrolled 45 patients with inoperable pancreatic cancer at the Heidelberg ...
VAXIMM receives grant to expand pipeline of oral cancer vaccines
08-10-2012
VAXIMM AG announced that its German subsidiary VAXIMM GmbH has been awarded a grant from the BioRN cluster “Cell-based and Molecular Medicine” to expand its oral T-cell vaccine technology platform. The cluster competition is a program of Germany´s Federal Ministry of Education and Research ...
Netmeeting
